About Bertis
Bertis is a company based in Seongnam-si (South Korea) founded in 2014 by Inhoi Koo and Jayden Jeewon P. It operates as a HealthTech and Professional Services. Bertis has raised $13.49 million across 1 funding round from investors including SK Planet. Bertis offers products and services including MASTOCHECK, PASS, and ProteoID. Bertis operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Seongnam-si, South Korea
- Founders Inhoi Koo, Jayden Jeewon P
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bertis Inc.
-
Annual Revenue
$1.22 M (USD)575as on Dec 31, 2022
-
Net Profit
-$17.62 M (USD)4as on Dec 31, 2022
-
EBITDA
-$17.39 M (USD)-53as on Dec 31, 2022
-
Total Equity Funding
$13.49 M (USD)
in 1 rounds
-
Latest Funding Round
$13.49 M (USD), Series B
Jun 03, 2021
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bertis
Bertis offers a comprehensive portfolio of products and services, including MASTOCHECK, PASS, and ProteoID.
Blood test for early breast cancer detection developed.
Pan-omics analysis service for biopharmaceutical research provided.
Core technology framework for proteomics analysis utilized.
Funding Insights of Bertis
Bertis has successfully raised a total of $13.49M through 1 strategic funding round. The most recent funding activity was a Series B round of $13.49 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bertis
Bertis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include SK Planet.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides marketing platforms, blockchain services, and business solutions using data infrastructure.
|
Locked | Locked | Locked |
Investor details for Bertis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bertis
Investment portfolio details for Bertis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bertis
Detailed financials for Bertis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bertis Comparisons
Peer comparison for Bertis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bertis
Bertis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Bertis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bertis
Complete news archive for Bertis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bertis
Bertis was founded in 2014 and raised its 1st funding round 7 years after it was founded.
Bertis is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Seungman Han is the current CEO of Bertis.
Bertis is a funded company, having raised a total of $13.49M across 1 funding round to date.
Annual revenue of Bertis is $1.22M as on Dec 31, 2022.
Bertis is focused on the development of proteomics-based precision medicine technologies. The company operates in the healthcare and biotechnology sectors, offering innovative diagnostic solutions like MASTOCHECK for early breast cancer detection and PASS for pan-omics analysis in biopharmaceutical research. Strategic partnerships are established with organizations in Southeast Asia to expand the reach of blood-based cancer screening tools. Additionally, research in skin proteomics is conducted in collaboration with global cosmetic leaders. The proprietary ProteoID platform is utilized to support advancements in early disease diagnosis and personalized treatment solutions across diverse healthcare systems.
Bertis's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Bertis offers MASTOCHECK, PASS, and ProteoID.
Bertis has 1 investor. Key investors include SK Planet.